Anti TNF therapy and susceptibility for Coxiella burnetii infectio

Completed

Conditions: Coxiella burnetii infection
Q fever
10003816
10004018

Registration Number: NL-OMON35680

Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 800

Inclusion Criteria

• Diagnosis of either rheumatoid arthritis (RA), arthritis psoriatica or bechterew disease
• Residence in Q fever endemic area (defined by the Institute for Public Health and Environment (RIVM) as *core area*), as determined by the postal code of their home address.
• Signed written informed consent ;For patients on anti-TNF therapy:
• Treatment with TNFa blockers either infliximab, etanercept or adalimumab in an adequate dose according to the guidelines
• Treatment with TNFa blockers is started before 01-01-2011 ;For patients not receiving anti-TNF therapy:
• Treatment with DMARDs
• No history of treatment with TNFa blockers

Exclusion Criteria

• Age under 18 years
• Pregnancy or lactation
• Lymphoma, lymphoproliferative syndromes and other hematologic malignancies
• Chronic infections, including HIV, hepatitis B or C, mycobacterial disease

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Serology indicative of chronic Q fever or past Q fever infection.<br /><br>In-vitro cytokine production and/or monocyte/macrophage polarisation.<br /><br>The presence of genetic polymorphisms in genes involved in the innate immunity. </p><br>

Secondary Outcome Measures